您当前所在的位置:首页 > 产品中心 > 产品信息
Tolazamide_分子结构_CAS_1156-19-0)
点击图片或这里关闭

Tolazamide

产品号 DB00839 公司名称 DrugBank
CAS号 1156-19-0 公司网站 http://www.ualberta.ca/
分子式 C14H21N3O3S 电 话 (780) 492-3111
分子量 311.39984 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 718

产品价格信息

请登录

产品别名

标题
Tolazamide
IUPAC标准名
1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea
IUPAC传统名
1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea
商标名
Tolinase
Tolanase
Norglycin

产品登记号

PubChem CID 5503
PubChem SID 46505642
CAS号 1156-19-0

产品性质

疏水性(logP) 2.5
溶解度 Solubility at pH 6.0 (mean urinary pH) is 27.8 mg/100 mL

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. [PubChem]
Indication For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
Pharmacology Tolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide, may become unresponsive or poorly responsive over time. Alternatively, tolazamide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance.
Toxicity Overdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.
Affected Organisms
Humans and other mammals
Biotransformation Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.
Absorption Rapidly and well absorbed from the gastrointestinal tract.
Half Life The average biological half-life of the drug is 7 hours.
Elimination Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.
External Links
Wikipedia
RxList
Drugs.com

参考文献